Genovis NIMT technology successfully meets expectations in important reference projects

Genovis NIMT technology successfully meets expectations in important reference
projects

In the autumn of 2006, Genovis mandated eight different research groups, from
both the academic as well as the industrial worlds, to perform different tests
of the NIMT™ technology developed by Genovis. The results show that the
technology from Genovis is highly competitive, that it works for gene transfer,
magnetic labeling and siRNA delivery, and that it can be used for different
types of cells. Genovis is a biotechnology company that develops and markets
innovative tools for medical research and the company's shares are listed on the
First North Stock Exchange in Stockholm.

Since the fourth quarter of 2006, Genovis has conducted a number of reference
projects. Genovis NIMT™ technology has been tested by eight different research
groups in applications involving gene transfer, magnetic labeling and siRNA
delivery. The groups are located at two Swedish biotechnology companies, Lund
University, Karolinska Institutet, Uppsala University, NIH (the National
Institute of Health, in the US) and SCRIPPS Research Institute (also in the US).


The objectives Genovis for this reference project included performing quality
assurance of the technology by testing its technical performance on cells that
the customers had defined as difficult to work with. The project has also given
Genovis valuable feedback regarding production, logistics and packaging
solutions. On the whole, the project has provided Genovis with additional
know-how that is useful in customer support and customized solutions in
different prioritized customer segments.

“Now we know that our technology meets our own expectations as well as those of
our customers”, says Sarah Fredriksson, CEO of Genovis. “We have a receipt
showing that our NIMT™ technology is competitive internationally.” 

The different research groups have worked with one or more different cells (for
a complete list of the cells tested, see the homepage for Genovis at
www.genovis.com). The reference groups have selected cells that are difficult or
sensitive to work with, and for which they have actively searched for new
methods that are milder to the cell. The NIMT™ technology from Genovis has
turned out to be the answer.

“By running these projects we have had the opportunity to view our NIMT™
technology through the eyes of our customers, which is crucial to our future
development work,” continues Sarah Fredriksson, CEO of Genovis. “Our
nanoparticles, the NIMT™FeOdots, can easily be modified to suit customer needs.
This shows the potential of the technology and it means that we can offer our
customers great flexibility.”

Genovis will begin sales of its NIMT™ technology for gene transfer, magnetic
labeling and siRNA delivery on a direct basis to its customers on 27 September
this year.

Sarah Fredriksson
CEO Genovis AB



For further information please contact:
Sarah Fredriksson
Genovis AB, Tel: (+46) (0)46-101230
E-mail: Sarah.Fredriksson@genovis.com
www.genovis.com